Browsing Tag
Lupin
82 posts
FDA concludes inspection at Lupin Bioresearch Centre in Pune
Lupin said that the US Food and Drug Administration (FDA) has concluded an inspection of the company’s bioresearch…
Can Lupin’s clean FDA inspection at its Vizag API plant boost confidence in its global supply reliability?
Lupin’s Vizag API plant clears US FDA inspection with no observations, strengthening its US supply reliability and regulatory track record.
Lupin launches Lurasidone Hydrochloride in US, targeting $4.2bn bipolar depression market
Lupin launches Lurasidone Hydrochloride Tablets in the US, entering a $4.2B bipolar depression market with a full range of strengths.
Lupin secures US FDA approval for generic Fesoterodine Fumarate Extended-Release Tablets in overactive bladder treatment market
Lupin secures US FDA approval for generic Fesoterodine Fumarate ER tablets, entering a USD 177M overactive bladder market in the United States.
Lupin ropes in Spiro Gavaris as US generics business president
Indian pharmaceutical company Lupin Limited has appointed Spiro Gavaris as president of its US generics business. Spiro Gavaris,…
Lupin launches authorized generic of PENNSAID in US to tap $509m osteoarthritis knee pain market
Lupin launches the authorized generic of PENNSAID in the U.S., targeting the $509M osteoarthritis knee pain market with a proven, cost-effective NSAID solution.
Is this Lupin’s next U.S. respiratory blockbuster? Generic Perforomist hits the shelves
Lupin launches generic Perforomist in the U.S. for asthma and COPD, eyeing a $268M market. Find out how this move boosts its global respiratory portfolio.
Lupin subsidiary MedQuĂmica buys rights to nine drugs from Bausch Health
Lupin Limited said that MedQuĂmica IndĂşstria FarmacĂŞutica, its 100% subsidiary in Brazil, has agreed to acquire all rights…
Lupin Limited secures US FDA tentative approval for generic version of rosacea drug Oracea
Lupin Limited gains US FDA tentative approval for generic Oracea, targeting the $215M rosacea drug market in the US.
Lupin secures US FDA tentative approval for generic version of Slynd contraceptive tablets
Lupin wins US FDA tentative approval for generic drospirenone contraceptive, targeting a $141M US market. See how this move fits its women’s health strategy.